[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"panic-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:panic-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,48,77,102,143,168,218,242,270,302,335,364,385,416,446,467,490,515,539,564,594,618,642,663,687],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100643199","serotonin-variants--gut-microbiota-in-mental-health-100643199",false,"NCT07634458","Serotonin Variants & Gut Microbiota in Mental Health","Association Between Serotonin Pathway Genetic Variants and Tryptophan-Metabolizing Gut Microbiota in Adults With Mental Health Conditions: An Observational Pilot Study","Inclusion Criteria:\n\n1. Age: Adults aged 18 to 44 years.\n2. Residency: Current legal residents of the United States.\n3. Clinical Phenotype: Self-report of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), or Panic Disorder.\n4. Medication Stability: If currently prescribed psychotropic medications (e.g., SSRIs, SNRIs, benzodiazepines), the dosage must remain stable with no changes in molecule or quantity for at least 3 months prior to enrollment.\n5. Language and Technology: Proficiency in English and access to a smartphone or computer for digital data entry.\n6. Financial Commitment: Explicit agreement to the \"Citizen Science\" model, including payment for discounted testing kits. Kit shipping (both directions) is prepaid by the study.\n\nExclusion Criteria:\n\n1. Use of systemic antibiotics, antifungals, or antivirals within the 8 weeks prior to specimen collection.\n2. Regular use of commercial probiotics or concentrated prebiotic supplements within 4 weeks of collection.\n3. Frequent use of osmotic or stimulant laxatives, or motility agents, within 4 weeks of collection.\n4. Chronic use (\\>3 times\u002Fweek) of NSAIDs, systemic corticosteroids, or high-dose Omega-3 supplementation (\\>2g\u002Fday) within 4 weeks of enrollment.\n5. Use of weight-loss medications or GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) within the 3 months prior to enrollment.\n6. Confirmed diagnosis of Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (Crohn's or Ulcerative Colitis), Celiac Disease, or history of major gastric\u002Fintestinal resection.\n7. Current pregnancy or lactation.\n8. Presence of cognitive impairments that preclude the ability to provide informed consent.\n9. Individuals undergoing active cancer treatment.","ALL","18 Years","44 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","This observational pilot study investigates whether a broad panel of genetic variants relevant to the serotonin pathway (including serotonergic system, methylation cycle, intestinal barrier integrity, and inflammatory response genes) are associated with distinct gut microbiome compositional and functional signatures in adults aged 18-44 years with self-reported mental health conditions (Major Depressive Disorder, Generalized Anxiety Disorder, PTSD, or Panic Disorder).\n\nThis is a decentralized, participant-funded (Citizen Science) study. Eligible participants provide at-home saliva (buccal swab) and stool samples. Genomic analysis is performed using the NeuroBiologix GenePro+ SNP Panel (Illumina Infinium Global Screening Array-24, \\~654,000 SNPs) via Gene By Gene, a CLIA\u002FCAP-accredited laboratory. Gut microbiome analysis is performed by Tiny Health using deep whole-genome shotgun metagenomics (≥20 million reads) on a NextGen Illumina Platform.\n\nThe study is non-interventional and hypothesis-generating, aiming to identify potential genotype-microbiome associations and estimate effect sizes to inform a future interventional trial. N=30 participants. Study Start: July 2026.",[25,26,27,28],"Major Depressive Disorder (MDD","Anxiety Disorder, Generalized","Stress Disorders, Post-Traumatic","Panic Disorder",[30,31,32,33,34,35],"gut microbiome","serotonin","tryptophan metabolism","metagenomics","SNP genotyping","gut-brain axis","NOT_YET_RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-10","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2027-09",{"name":46,"class":47},"Neurobiologix","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100475189","co2-reactivity-as-a-biomarker-of-non-response-to-exposure-based-therapy-100475189","NCT05467683","CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Carbon Dioxide (CO2) Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy","Inclusion Criteria:\n\n* A primary DSM-5 diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder as assessed by the Structured Clinical Interview for the DSM-5 (SCID-5)\n* A score of 8 or greater on the Overall Anxiety Severity and Impairment Scale (OASIS)\n* Ages 18 to 70\n* Willingness and ability to provide informed consent and comply with the requirements of the study protocol.\n* Proficiency in English (because assessment instruments have only been validated in English)\n\nExclusion Criteria:\n\n* A lifetime history of bipolar or psychotic disorders, substance use disorders (other than nicotine) or eating disorder in the past 6 months; serious cognitive impairment.\n* Active suicidal ideation with at least some intent to act with or without specific plan (a rating of 4 for suicidal ideation on the Columbia-Suicide Severity Rating Scale) or suicidal behaviors (actual attempt, interrupted attempt, aborted or self-interrupted attempt, or preparatory acts or behavior) within the past 6 months.\n* Medical conditions contraindicating CO2 inhalation or hyperventilation challenge (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke).\n* Pregnancy or lactation\n* Ongoing psychotherapy directed toward the primary disorder.\n* Pharmacological treatment started within 8 weeks prior to the screen (patients \"stable\" on their medication regimen will be included and their medication status will be included as a variable in the model)","70 Years",{"count":57,"type":21},600,"INTERVENTIONAL",[60],"NA","Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question \"can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?\"",[63,64,65,66,28],"Obsessive-Compulsive Disorder","Post Traumatic Stress Disorder","Generalized Anxiety Disorder","Social Anxiety Disorder","RECRUITING",{"date":39,"type":40},{"date":70,"type":40},"2022-11-02",{"date":72,"type":21},"2027-02-28",{"name":74,"class":75},"Jasper A. Smits","OTHER",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100559375","neurofeedback-enhanced-cognitive-reappraisal-training---phase-4-100559375","NCT06563310","Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4","Inclusion Criteria:\n\n* Primary diagnosis (primary source of distress and\u002For interference) of generalized anxiety disorder, social anxiety disorder, panic disorder or illness anxiety disorder based on structured interview. Comorbid phobic disorders allowed, but these cannot be the primary source of interference or distress due to the lowered chances of encountering anxiety-provoking stimuli during the study period\n* Score of 2 or more on at least 1 question from GAD\u002FCROSS-AD composite\n* Medically and physically able to consent\n* Not regularly taking any medication, prescription or non-prescription, with psychotropic effects other than:\n\n  1. Buspirone, or antidepressant (e.g., selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)) with stable dosage for past 4 weeks\n  2. The same oral hormonal contraceptive for at least 3 months\n* For females, not currently pregnant or actively trying to become pregnant\n* Ability to tolerate small, enclosed spaces without anxiety\n* No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition (per protocol)\n* Size compatible with scanner gantry (per protocol)\n\nExclusion Criteria:\n\n* Current diagnosis of Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, or Bipolar Disorder\n* Current substance abuse or dependence (past 6 months)\n* Active suicidality with plan or intent\n* Current psychosis\n* History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure\n* History of closed head injury, e.g., loss of consciousness greater (\\>) approximately (\\~) 5 minutes, hospitalization, neurological sequela","24 Years",{"count":85,"type":21},110,[60],"This study seeks to understand emotion regulation in those with young adults with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control brain activity. The goal of this project is to understand how receiving feedback about one's own brain activity relates to emotion regulation ability. This work will help the study team understand the brain areas involved in emotion regulation and could lay the groundwork to test if psychotherapy outcomes can be enhanced using neurofeedback.\n\nThe study hypotheses include:\n\n* Participants receiving veritable-Neurofeedback (NF) will show a greater activation increases in the prefrontal cortex (PFC) compared to sham-NF\n* Participants receiving veritable-NF will show greater cognitive reappraisal (CR) ability compared to those receiving sham-NF\n* PFC activation will positively correlate with CR ability",[89,66,28,65],"Anxiety",[91],"functional magnetic resonance imaging","2026-06-03",{"date":94,"type":40},"2026-06-05",{"date":96,"type":40},"2025-01-09",{"date":98,"type":21},"2029-05",{"name":100,"class":75},"University of Michigan",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":17,"enrollmentInfo":111,"targetDuration":4,"studyType":58,"phases":113,"briefSummary":114,"conditions":115,"keywords":127,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":101},"100587910","implementing-team-based-treatment-for-pediatric-anxiety-in-community-mental-health-settings-100587910","NCT06934525","Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings","Testing Delivery of Modalities in Community Health Settings: Developing Pathways to Health Equity","IMPACT-RI","Inclusion Criteria:\n\n* Age 5-18 inclusive\n* Primary or co-primary DSM-V diagnosis of anxiety or OCD\n* Symptom duration of at least 3 months\n* Outpatient care needed\n* Presence of a stable parent, or guardian, who can participate in treatment\n\nExclusion Criteria:\n\n* Other primary or co-primary psychiatric disorder which requires initiation of other active current treatment\n* Acute suicidality\n* Concurrent psychotherapy\n* Chronic medical illness that would preclude their active participation in treatment\n* Treatment with psychotropic medication that is not stable","5 Years",{"count":112,"type":21},501,[60],"The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home\u002Fcommunity), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and\u002For telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom.\n\nTreatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health.\n\nThe research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.",[116,117,118,89,119,120,121,122,65,123,124,125,66,28,126],"Obsessive Compulsive Disorder (OCD)","Pediatric Anxiety Disorders","Anxiety Disorder","OCD","Phobia","Agoraphobia","Generalized Anxiety","Selective Mutism","Separation Anxiety","Social Anxiety","Pediatric Disorders",[128,129,130,131,132,133],"exposure therapy","cognitive behavioral therapy","anxiety treatment","exposure and response prevention therapy","ERP","pediatric anxiety treatment","2026-05-13",{"date":136,"type":40},"2026-05-14",{"date":138,"type":40},"2025-11-01",{"date":140,"type":21},"2029-08-01",{"name":142,"class":75},"Bradley Hospital",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":58,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":101},"100595112","mindful-self-compassion-for-anxiety-and-depression-impact-of-delivery-method-100595112","NCT07028216","Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method","Mindful Self-Compassion for Anxiety and Depression: A Randomized Comparison of In-Person Versus Videoconference Delivery","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* Must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners","65 Years",{"count":152,"type":21},80,[60],"The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.",[156,65,66,28,121,157,158],"Anxiety Disorders","Major Depressive Disorder","Persistent Depressive Disorder (Dysthymia)","2026-05-03",{"date":161,"type":40},"2026-05-05",{"date":163,"type":40},"2025-06-01",{"date":165,"type":21},"2027-08-31",{"name":167,"class":75},"Georgetown University",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":178,"conditions":179,"keywords":202,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":101},"100577917","lhc-cidi-5-in-hong-kong-100577917","NCT06804525","LHC-CIDI-5 in Hong Kong","Use of Life History Calendars to Enhance Measurement of Lifetime Experience With Mental Disorders in Hong Kong.","Inclusion Criteria:\n\n* All household members aged 25 years old and over are randomly sampled from the Census and Statistics Department List of Quarters\n* Live in the address sampled from the Census and Statistics Department List of Quarters\n* Reside in Hong Kong for at least six months in the past year\n* Able to read and communicate in Chinese or English\n* Without linguistic or cognitive difficulties\n\nExclusion Criteria:\n\n* Domestic workers","25 Years",{"count":177,"type":21},2500,"The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders.\n\nTo mitigate this issue, the life history calendar (LHC) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the CIDI-5 to measure the lifetime prevalence of mental disorders. The LHC is a grid structure with columns representing time units and rows representing life domains under study.\n\nIn a study conducted in Nepal, combining the CIDI-5 with the LHC resulted in a significant increase in the detection of mental disorders compared to using the CIDI-5 alone. This approach did not lead to an increase in false positives after clinical validation.\n\nThis experiment aims to adapt a Hong Kong version of the LHC based on the Nepalese model and evaluate the effectiveness of the LHC-assisted CIDI-5 (LHC-CIDI-5) compared to the CIDI-5 alone in assessing mental disorders.",[180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,28,196,197,198,199,200,201],"Major Depressive Episode (MDE)","Major Depressive Disorder (MDD)","Persistent Depressive Disorder (PDD)","Suicidal Ideation","Suicidal Plan","Suicidal Attempt","Suicidal Gesture","Nonsuicidal Self-Injury","Manic Episode","Hypomanic","Bipolar I Disorder","Bipolar Sub Disorder","Bipolar II Disorder","Generalized Anxiety Disorder (GAD)","Intermittent Explosive Disorder (IED)","Panic Attack","Obsessive-Compulsive Disorder (OCD)","Posttraumatic Stress Disorder (PTSD)","PCL-SC PTSD","PCL-5 PTSD","Alcohol Use Disorder (AUD)","Substance Use Disorder (SUD)",[203,204,205,206,207,208],"Life History Calendar","CIDI","Recall bias","Retrospective reporting","Lifetime prevalence","Mental disorders","2026-03-09",{"date":211,"type":40},"2026-03-10",{"date":213,"type":40},"2025-01-18",{"date":215,"type":21},"2027-04",{"name":217,"class":75},"The University of Hong Kong",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":58,"phases":229,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":101},"100285658","the-use-of-a-fda-cleared-drug-free-breathing-system-for-anxiety-and-panic-disorders-in-children-and-teens-100285658","NCT02998502","The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens","Efficacy of a Biofeedback Breathing System for Anxiety and Panic Disorders","Inclusion Criteria:\n\n* SCARED score ≥ 25 + prior clinical diagnosis of an anxiety disorder\n* Participants must be 9-17 years of age\n* If on psychotropic medication(s), participant must be on a stable dose for at least one month prior to study enrollment\n\nExclusion Criteria:\n\n* Anxiety has occurred exclusively during a major depressive episode, psychiatric illness, dementia, intellectual disability, or brain disease\n* Currently enrolled in another device or drug study or less than 30 days has elapsed since participation in such a study\n* Currently undergoing breathing biofeedback elsewhere\n* Demonstrate evidence of severe suicidal ideation or psychosis\n* There is an active condition of asthma","9 Years","17 Years",{"count":228,"type":21},73,[60],"This study will test the efficiency of the Freespira Breathing System in youth.",[89,28],[116,89,233],"Pediatrics","2026-03-05",{"date":209,"type":40},{"date":237,"type":21},"2026-08-01",{"date":239,"type":21},"2027-03-01",{"name":241,"class":75},"Johns Hopkins University",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":249,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":101},"100627149","il-33-sst2-and-crp-in-panic-disorder-100627149","NCT07444879","IL-33, sST2, and CRP in Panic Disorder","Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study","1. For Panic Disorder (PD) Group:\n\n   \\*Inclusion Criteria:\n   * Being between 18-65 years of age\n   * Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder\n   * Not having previously used any medication for psychiatric purposes (drug-naive)\n   * Not having any additional active psychiatric disorders besides PD at the current presentation\n   * Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n   * Not having taken any medication or supplements in the last month\n   * Completing sociodemographic and scale data fully\n   * Volunteering to participate in the study\n\n   For PD Group:\n\n   \\*Exclusion Criteria:\n\n   • Being outside the 18-65 age range\n\n   • Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health\n\n   • Having a history of psychiatric medication use\n\n   • Having an additional psychiatric disorder besides PD at the current application\n\n   • Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer\n\n   • Patients with a body mass index (BMI) \\\u003C18.5 kg\u002Fm² and \\>29.9 kg\u002Fm²\n   * Taking any medication or supplement in the last month\n   * Incomplete completion of sociodemographic and scale data\n   * Not volunteering to participate in the study\n2. For Healthy Control Group:\n\n   * Inclusion Criteria:\n\n     * Being between 18-65 years of age\n     * Not having any active psychiatric disorder\n     * Not having previously used any medication for psychiatric purposes (drug-naive)\n     * Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n     * Not having taken any medication or supplement in the last month\n     * Completing sociodemographic and scale data fully\n     * Volunteering to participate in the study\n\nFor Healthy Control Group:\n\n\\*Exclusion Criteria:\n\n* Being outside the 18-65 age range\n* Having any active psychiatric disorder\n* Having a history of using psychiatric medication\n* Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer\n* Patients with a body mass index (BMI) \\\u003C 18.5 kg\u002Fm² and \\> 29.9 kg\u002Fm²\n* Taking any medication or supplement in the last month\n* Incomplete completion of sociodemographic and scale data\n* Not volunteering to participate in the study",true,{"count":152,"type":21},"Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33\u002FsST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.",[28],[28,254,255,256,257,258,259],"Interleukin-33","IL-33","Soluble Suppressor Tumorogenicity-2","sST2","CRP","C-Reactive Protein","2026-03-02",{"date":262,"type":40},"2026-03-04",{"date":264,"type":40},"2025-07-07",{"date":266,"type":21},"2026-03-23",{"name":268,"class":269},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":277,"maxAge":226,"enrollmentInfo":278,"targetDuration":4,"studyType":58,"phases":280,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":101},"100588517","stepped-versus-stratified-care-for-anxiety-disorders-in-youth-100588517","NCT06942429","Stepped Versus Stratified Care for Anxiety Disorders in Youth","Stepped Versus Stratified Care for Anxiety Disorders in Youth: A Pragmatic Non-Inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 8.0 to 17.5 years. Confirmed by the child and\u002For caregiver.\n2. Principal DSM-5-TR anxiety disorder of social anxiety disorder, generalized anxiety disorder, panic disorder, separation anxiety disorder, specific phobia, or agoraphobia. Confirmed by the structured diagnostic interview (DIAMOND-KID). \"Principal\" indicates that the anxiety disorder is judged by the clinician to be in most urgent need of treatment (among potential co-occurring disorders).\n3. Available caregiver who can support the child in treatment. Confirmed by the caregiver.\n4. Child and at least one caregiver can read, write, and communicate in Swedish. Confirmed by the child and\u002For caregiver.\n5. Child (≥13 years) and caregiver have access to a Swedish electronic identification (BankID or Freja eID).\n6. Access to the internet. Confirmed by the child and\u002For caregiver.\n7. Ability to attend in-person CBT sessions at the clinic. Confirmed by the child and\u002For caregiver.\n\nExclusion Criteria:\n\n1. Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises). Confirmed by a specific phobia of this sort being classified as the most functionally impairing anxiety disorder during the structured diagnostic interview (DIAMOND-KID).\n2. Ongoing psychological treatment for an anxiety disorder. Confirmed by the child and\u002For caregiver.\n3. Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder. Confirmed by the assessor through information from the child and\u002For caregiver and\u002For other available sources.\n4. Immediate risk to self or others that require urgent attention, such as suicidality. Confirmed by the assessor through information from the child and\u002For caregiver and other available sources.\n5. The potential participant has a relative (e.g., sibling, cousin) included in the study. Confirmed by the assessor through information from the caregiver and other available sources.","8 Years",{"count":279,"type":21},556,[60],"The goal of this clinical trial is to compare stepped care to stratified care as overall healthcare models for children and adolescents aged 8-17 with anxiety disorders. It addresses one main question:\n\n• Is stepped care non-inferior to stratified care in supporting participants to achieve a treatment response?\n\nResearchers will compare two care models:\n\n* Stepped care, where all participants begin with 14 weeks of internet-delivered cognitive behavioral therapy (ICBT) and receive an additional 14 weeks of personalized in-person CBT if needed.\n* Stratified care, where participants are assigned to either 14 weeks of ICBT or 14 weeks of in-person CBT based on clinical complexity, and may also receive additional 14 weeks of in-person CBT if necessary.\n\nParticipants will:\n\n* Be randomly assigned to one of the two care models.\n* Complete a wide range of assessments at baseline, during treatment, and at 4, 8, 12, and 24 months, with the 8-month point as the primary endpoint.\n* Receive either ICBT, in-person CBT, or both, depending on their care model and response to treatment.\n* Participate in ancillary studies involving DNA sampling, cognitive testing, and national registry linkages to help predict treatment response and long-term outcomes.",[66,283,284,28,65,121],"Separation Anxiety Disorder","Specific Phobia",[286,287,288,129,289,290,291,292],"anxiety disorders","children","adolescents","non-inferiority","care models","stepped care","stratified care","2026-02-24",{"date":295,"type":40},"2026-02-27",{"date":297,"type":40},"2025-06-19",{"date":299,"type":21},"2031-03-05",{"name":301,"class":75},"Region Skane",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":309,"targetDuration":4,"studyType":58,"phases":311,"briefSummary":312,"conditions":313,"keywords":318,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":101},"100626714","qigong-and-multicomponent-exercise-in-panic-disorder-100626714","NCT07439224","Qigong and Multicomponent Exercise in Panic Disorder","Investigation of the Effects of Qigong Exercise Training and Multicomponent Exercise Training on Physical and Mental Health in People With Panic Disorder","Inclusion Criteria:\n\n* Being between the ages of 18-65\n* Being diagnosed with \"panic disorder\" by a psychiatrist\n* Not having another psychiatric illness\n* Wanting to participate in the research voluntarily and signing the informed consent\n* Not having a history of communication or neuromusculoskeletal disease that would not allow the application of evaluation and treatment methods\n\nExclusion Criteria:\n\n* Having a vision and\u002For hearing problem that would prevent participation in the study\n* History of neurological, cardiopulmonary and musculoskeletal system disease that would negatively affect participation in evaluation and treatment",{"count":310,"type":21},60,[60],"Panic disorder is a psychiatric disease characterized by recurrent panic attacks that occur in expected or unexpected situations and create feelings of intense fear, restlessness and discomfort. Panic disorder often has a chronic course, its frequency and severity can be irregular, various physical, mental, and behavioral symptoms can develop, and the quality of life of individuals can decrease significantly. Evidence-based psychotherapy and pharmacotherapy are effective in reducing the symptoms of panic disorder and managing the disorder. However, both of these treatment methods have certain limitations, and approximately one-third of patients do not respond to therapy or the response is not sufficiently effective. Delaying treatment of the disease results in a poor prognosis and more established symptoms. Exercise can be viewed as a low-cost, supportive treatment for relieving symptoms with comparable efficacy to medication and other psychological interventions. Although exercise is recommended for patients with anxiety-panic disorder, there remains uncertainty about whether its effects are sustainable, the type and intensity of exercise required for effective treatment, and thus the effects of qigong and multicomponent exercise on multiple health outcomes in panic disorder. The aim of this study is to examine the effects of Qigong exercise training and multicomponent exercise training on anxiety-panic, balance, mobility, walking, functional strength, physical activity, sleep quality, fatigue, chronic musculoskeletal pain, quality of life and cognition.",[28,314,315,316,317,156],"Panic Disorder (With or Without Agoraphobia)","Panic Attacks and Disorders","Qigong","Exercise",[319,320,321,322,323,324,325,316,326],"Anxiety disorders","Baduanjin","Exercise training","Physical health","Mental health","Multicomponent exercise","Panic disorder","Mind-body exercises","2026-02-23",{"date":295,"type":40},{"date":330,"type":40},"2024-12-01",{"date":332,"type":21},"2028-09-30",{"name":334,"class":75},"Dokuz Eylul University",{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":277,"maxAge":226,"enrollmentInfo":342,"targetDuration":4,"studyType":58,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":101},"100566921","internet-delivered-cognitive-behavioral-intervention-for-youths-with-anxiety-disorders-100566921","NCT06661460","Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Development and Preliminary Evaluation of a New Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Inclusion Criteria:\n\n1\\) 8 to \\\u003C18 years of age.\n\n* Confirmed by the child\u002Fcaregiver and subsequently by the medical record system. 2) A principal DSM-5-TR anxiety disorder of specific phobia, separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, panic disorder or agoraphobia.\n* Confirmed by the Diagnostic Interview for Anxiety, Mood, and OCD and related Neuropsychiatric Disorders - Child and Adolescent Version (DIAMOND-KID).\n\n  3\\) Child and caregiver able to read, write and communicate in Swedish.\n* Confirmed by the child\u002Fcaregiver. 4) An available caregiver who can support the child in treatment.\n* Confirmed by the caregiver. 5) Access to a smartphone, tablet, or laptop\u002Fdesktop device, and the internet.\n* Confirmed by the child\u002Fcaregiver.\n\nExclusion Criteria:\n\n1\\) Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises).\n\n* Confirmed by a blood-injection-injury phobia being classified as the principal anxiety disorder as assessed by the DIAMOND-KID.\n\n  2\\) Established or suspected intellectual disability.\n* Confirmed by the caregiver (through previous diagnosis) and\u002For by attending a special needs school for learning difficulties.\n\n  3\\) Another mental disorder in more immediate need of management than an anxiety disorder (e.g., schizophrenia spectrum and other psychotic disorders, bipolar disorder, anorexia nervosa, substance use disorders).\n* According to the DIAMOND-KID and\u002For other available sources. 4) Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and\u002For other available sources.\n\n  5\\) Immediate risk to self or others that require urgent attention, such as acute suicidality.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and other available sources.\n\n  6\\) Previous CBT for an anxiety disorder, defined as five or more sessions with a certified CBT therapist within the 12 months prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 7) Ongoing psychological treatment for an anxiety disorder.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 8) Initiation or adjustment of any psychotropic medication for anxiety (i.e., selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitor or antipsychotics) within 8 weeks prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 9) Participation in user involvement sessions in the present study.\n* Confirmed by the researcher.",{"count":343,"type":21},48,[60],"The goal of this study is to develop a new internet-delivered cognitive behavioral therapy (ICBT) intervention for youths with anxiety disorders based on the best current knowledge about effective cognitive behavioral therapy for the target group, refine the intervention in collaboration with patient and public representatives, and conduct a preliminary evaluation of the treatment effects in an open clinical trial.\n\nThe primary objective of the study is:\n\n1\\. To evaluate the preliminary efficacy of a newly developed ICBT intervention for children and adolescents with anxiety disorders in reducing anxiety severity, as measured by the Pediatric Anxiety Rating Scale (PARS).\n\nSecondary objectives of the study are:\n\n1. To examine the preliminary efficacy (PARS) of the ICBT intervention at 3 months post-treatment.\n2. To examine how youths with anxiety disorders, their caregivers, therapists, and healthcare leadership experience the ICBT intervention.\n3. To examine factors (e.g., age, type of anxiety disorder, presence of depressive symptoms, experiences of ICBT) that predict treatment outcome.\n4. To examine how the ICBT intervention can be improved (e.g., treatment content and technical delivery) for future use.\n\nParticipants will:\n\n* Undergo ICBT treatment for anxiety disorders during 12 weeks\n* Complete questionnaires at multiple time points throughout the study\n* Participate in follow-ups post-treatment and 3 months post-treatment\n* A selection of participants will also be invited to focus group interviews with the aim to generate ideas on how the intervention may be improved for future use",[347,284,66,283,65,28,121],"ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)",[319,349,350,351,352,353,354],"Children","Adolescents","Cognitive Behavioral Therapy","Remote delivery","Internet","Internet-delivered cognitive behavioral therapy","2026-02-19",{"date":357,"type":40},"2026-02-20",{"date":359,"type":40},"2025-12-12",{"date":361,"type":21},"2027-06-01",{"name":363,"class":75},"Lund University",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":370,"targetDuration":4,"studyType":58,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":383,"locationsCount":101},"100448269","validating-an-autonomous-interactive-internet-based-delivery-of-an-empirically-supported-cognitive-behavioral-therapy-for-comorbidity-100448269","NCT05117255","Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity","Inclusion Criteria:\n\n* current (past 30 days) Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of panic disorder with or without agoraphobia (PD\u002FAg), generalized anxiety disorder (GAD) or social anxiety disorder (SAD)\n* receiving treatment primarily for alcohol (vs. drug) dependence\n* ability to provide informed consent\n* a minimum of an eighth grade English reading level\n* status as a residential patient in the Lodging Plus (LP) addiction treatment program\n* sufficient time left in their residential LP care to complete the study protocol through the post-treatment assessment\n\nExclusion Criteria:\n\n* cognitive or medical impairments that prohibit study participation as determined by study PI\n* serious suicide risk determined by study PI\n* court-ordered treatment. (The exclusion is based on its classification as a \"vulnerable\" population.)\n* Self-reported past participation in a Kushner intervention study while in Lodging Plus",{"count":371,"type":21},256,[60],"This project is designed to determine if a computer-delivered cognitive-behavioral treatment can improve the otherwise poor alcohol use disorder treatment outcomes for individuals with a co-occurring anxiety disorder. In the past, the investigators showed that this treatment does improve outcomes for these individuals when delivered by a therapist. If the present work shows that the computer-delivered version is also effective, it would provide an inexpensive program with virtually unlimited scalability to enable access to the treatment by many more individuals than is currently the case.",[65,28,66,375,376],"Alcohol Use Disorder","Depression","2025-12-09",{"date":379,"type":40},"2025-12-17",{"date":381,"type":40},"2022-01-04",{"date":239,"type":21},{"name":384,"class":75},"University of Minnesota",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":58,"phases":394,"briefSummary":395,"conditions":396,"keywords":402,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":101},"100472117","respiratory-training-in-the-treatment-of-transdiagnostic-pathological-anxiety-100472117","NCT05427708","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).\n2. Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their \"primary\" mental disorder:\n\n   * Generalized Anxiety Disorder\n   * Panic Disorder\n   * Health Anxiety\n   * Agoraphobia\n   * Social Anxiety Disorder\n   * Posttraumatic Stress Disorder\n   * Acute Stress Disorder\n   * Adjustment Disorder with primary anxious mood\n   * Anxiety disorder not otherwise specified\n3. No current use of psychotropic medications or stable on current medications for at least 6 weeks\n4. Age 18+.\n5. Able to arrange transportation to our laboratory for study appointments.\n6. Fluent in English.\n\nExclusion Criteria:\n\n1. No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:\n\n   * Cardiovascular or respiratory disorders\n   * High blood pressure\n   * Epilepsy\n   * Strokes\n   * Seizures\n   * History of fainting\n   * Pregnant or lactating\n2. Not currently receiving other psychological treatment for anxiety.\n3. No history of a suicide attempt within the past 6 months.\n4. No history of psychosis within the past 6 months.\n5. No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.\n6. Does not endorse COVID-19 symptoms during the screening phase.",{"count":393,"type":21},180,[60],"Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.",[156,397,65,28,121,398,66,399,400,401],"Trauma","Illness Anxiety Disorder","Posttraumatic Stress Disorder","Acute Stress Disorder","Adjustment Disorder With Anxious Mood",[403,404,405,406],"Psychoeducation","Respiratory training","Transdiagnostic","Intervention","2025-08-18",{"date":409,"type":40},"2025-08-24",{"date":411,"type":40},"2022-08-22",{"date":413,"type":21},"2027-05",{"name":415,"class":75},"University of Texas at Austin",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":423,"maxAge":226,"enrollmentInfo":424,"targetDuration":4,"studyType":58,"phases":426,"briefSummary":427,"conditions":428,"keywords":433,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":101},"100594846","comparative-effectiveness-of-internet-based-versus-parent-coached-cognitive-behavioral-therapy-for-children-and-adolescents-with-anxiety-and-ocd-100594846","NCT07024758","Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD","ASTRO","Inclusion Criteria:\n\n* The child is between the ages of 7 to 17 years inclusive at enrollment.\n* The child has clinically significant symptoms of anxiety and\u002For OCD, as indicated by a score of 12 or higher on the Pediatric Anxiety Rating Scale (PARS).\n* The child is appropriate for anxiety-focused treatment (e.g., anxiety or OCD is the primary or co-primary problem as diagnosed using the DIAMOND-KID).\n* One parent\u002Fguardian is able and willing to participate in assessment and treatment (e.g., has sufficient English fluency, the decisional capacity to participate, and can commit to treatment duration).\n* The participating parent\u002Fguardian lives with their child at least 50% of the time per self-report.\n* Both parent and child can read and understand English.\n* The participant has an IQ above 69, based on the KBIT-2, another valid test or clinician judgement (e.g., a previous assessment conducted, and report shared with study team).\n* Participants must be in the state of Texas for treatment sessions\u002Fassessments.\n\nExclusion Criteria:\n\n* The child has a diagnosis of a lifetime psychotic disorder and\u002For conduct disorder.\n* The child has significant, current and active suicidality\u002Fhomicidality and\u002For self-injury requiring medical intervention.\n* The child has limited verbal communication abilities (e.g., no independent verbal communication).\n* The child is receiving concurrent psychotherapy with anxiety and\u002For OCD as the primary focus. They can pause ongoing therapy to enroll.\n* The child has initiated new antidepressant medication within 12-weeks of assessment (4-weeks for stimulants\u002Fbenzodiazepines\u002Fantipsychotics) or during therapy.\n* The child has changed psychotropic medication dosage within 4-weeks of assessment (2-weeks for stimulants\u002Fbenzodiazepines\u002Fantipsychotics) or during therapy.\n* The child requires a higher level of care than can be provided through the study (e.g., significant, current suicidal ideation).","7 Years",{"count":425,"type":21},174,[60],"Anxiety disorders in children and adolescents are common and confer significant disability. Cognitive behavioral therapy (CBT) is the recommended treatment for youth with anxiety, yet many families cannot access CBT due to cost, practicalities of attending in-person treatment sessions, and a shortage of trained providers, especially in rural areas. To combat these barriers, other treatment methods have been developed.\n\nPrevious research has shown that family-based, internet-delivered CBT (iCBT) for anxiety and OCD in youth has shown a significant reduction in anxiety symptoms. Parent-coached exposure therapy (PCET) focuses entirely on teaching parents and youth together how to address anxiety through the completion of in-session parent-coached exposures and assigning parent-coached exposure as homework in between sessions.\n\nAlthough both iCBT and PCET show positive results in treating pediatric anxiety in comparison to standard-care CBT, little is known about the comparative efficacy of iCBT and PCET.\n\nThis research is being done to understand the comparative effectiveness of two different types of cognitive-behavioral therapy (CBT) for treating anxiety or OCD in youth.",[116,429,430,193,283,28,431,314,432],"Anxiety Disorder of Childhood or Adolescence","Social Anxiety Disorder of Childhood","Panic Attacks","Phobia, Specific",[434,435,436,287,288],"Obsessive-compulsive disorder","anxiety","cognitive-behavioral therapy","2025-07-18",{"date":439,"type":40},"2025-07-20",{"date":441,"type":40},"2025-07-01",{"date":443,"type":21},"2028-06-30",{"name":445,"class":75},"Baylor College of Medicine",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":58,"phases":455,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":101},"100490845","mindful-self-compassion-for-anxiety-disorders-and-depression-100490845","NCT05671419","Mindful Self-Compassion for Anxiety Disorders and Depression","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners","75 Years",{"count":454,"type":21},40,[60],"The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder.",[156,65,66,458,28,121,157],"Social Phobia","2025-06-10",{"date":461,"type":40},"2025-06-13",{"date":463,"type":40},"2022-01-16",{"date":465,"type":21},"2026-07",{"name":167,"class":75},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":489},"100505957","effects-and-cost-effectiveness-of-e-meistring---a-guided-internet-delivered-psychological-treatment-100505957","NCT05868135","Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment","Guided Internet-delivered Treatment for Moderate Depression, Social Anxiety Disorder and Panic Disorder - An Open Naturalistic Multicentre Cost-effectiveness Trial","Inclusion Criteria:\n\nHaving moderate depression, panic disorder and social anxiety disorder as a primary disorder. Access to computer and internet.\n\nExclusion Criteria:\n\nHaving severe depression, suicidal impulses and thoughts, bipolar disorders, psychosis, substance abuse, unstable medication last month, severe reading or writing disabilities.",{"count":475,"type":21},800,"The goal of this observational multicentre study is to address the effectiveness and cost-effectiveness of providing a therapist guided internet based cognitive behavioural therapy (ICBT) for common mental disorders in a routine healthcare setting.\n\nMain research questions is 1) What is the effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics in routine care? 2) What is the cost-effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics? 3) Who benefits from guided internet-delivered treatment? 4) What are the predictors of drop-out from guided internet based treatment? 5) To what extent does user experiences of guided internet based treatment influence adherence and effectiveness? Participants will receive up to nine guided ICBT sessions (modules) and answer questionnaires covering symptoms severity, health related quality of life, work and social ability, user satisfaction and medication. All questionnaires are part of the standard patient follow up routines in the four treatment locations participating in the study. Analytical approach is to compare locations\u002Fclinics and subgroups of patients.",[478,479,28],"Depression Moderate","Anxiety, Social","2025-06-04",{"date":482,"type":40},"2025-06-05",{"date":484,"type":40},"2021-09-09",{"date":486,"type":21},"2027-12-31",{"name":488,"class":75},"St. Olavs Hospital",4,{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":58,"phases":499,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":101},"100576655","analyzing-the-benefits-of-using-symptoms-jit-for-in-vivo-exposure-in-anxiety-disorders-100576655","NCT06788119","Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders","Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders: a Randomized Controlled Trial Using a Mixed Methods Approach","Inclusion Criteria:\n\n* Being at least 18 years or older.\n* Meeting DSM-5 diagnostic criteria (APA, 2013) for anxiety disorder, specifically specific phobia, agoraphobia, panic disorder and social phobia.\n* Being willing to follow the study conditions.\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Having another psychological problem that requires immediate attention.\n* Having current alcohol or drug dependence or abuse, psychosis or severe organic illness.\n* Currently being treated in a similar treatment program.\n* Taking anxiolytics during the study (or in the case of taking them, changing drug or dose during the study).",{"count":498,"type":21},158,[60],"The aim of this study is to develop and test the efficacy of first-of-its-kind, fully instrumented sensor-based smartphone-guided in-vivo exposure therapy using a just-in-time intervention for anxiety disorder. The main hypotheses are:\n\n1. Both treatment conditions (CBT treatment with IVE and CBT treatment with IVE+SYMPTOMS-JIT) will show efficacy and no statistically significant differences will be found between them. The efficacy will be determined for the differences in pre-post treatment in the used outcome measures.\n2. The therapeutic gains obtained in both treatment conditions (IVE and (IVE+SYMPTOMS-JIT) will be maintained at 1-, 6-, and 12-month follow-up periods.\n3. Both treatment conditions will be efficient, that is, they will be well-valued by patients and therapists. However, IVE+SYMPTOMS-JIT will be preferred and perceived as less aversive than IVE.\n4. The main barriers for the use of this technology are not technological, but rather attitudinal and they can be identified through qualitative studies.",[156,284,28,121,66],[319,503,504,505,506],"In vivo exposure","app","smartphone","smartwatch","2025-05-12",{"date":509,"type":40},"2025-05-16",{"date":511,"type":40},"2025-04-30",{"date":486,"type":21},{"name":514,"class":75},"Universitat Jaume I",{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":522,"targetDuration":4,"studyType":58,"phases":524,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":101},"100570219","psychoeducation-based-on-acceptance-and-commitment-therapy-100570219","NCT06704399","Psychoeducation Based on Acceptance and Commitment Therapy","Investigation of the Effect of Acceptance and Commitment Therapy-Based Psychoeducation on Rumination and Self-Compassion in Patients Diagnosed With Panic Disorder: Randomized Controlled Study","Inclusion Criteria:\n\n* Patients diagnosed with Panic Disorder followed in Muğla Training and\n* Research Hospital Psychiatry Polyclinics,\n* Those between the ages of 18-65 who agree to participate in the research,\n* Those who were in a euthymic mood during the interview, according to physician control,\n* Those who speak Turkish,\n* Those who are literate,\n* Those who have a computer and internet access for the program to be conducted online if deemed necessary during the research process,\n* Not having undergone such training within the last year is within the scope of the inclusion criteria.\n\nExclusion Criteria:\n\n* Having a diagnosis of a psychiatric disease in addition to panic disorder,\n* Having an attack period during the training period,\n* Individuals with cognitive (diagnosed by a physician) and physical disability (hearing, speaking, etc.) are included in the exclusion criteria from the study.",{"count":523,"type":21},50,[60],"The aim of this study is to manage individual psychoeducation in acceptance and commitment therapy for problems with panic disorder and to evaluate the effect of this program on rumination and self-resilience.",[28],[528,529],"rumination","self-compassion","2025-05-07",{"date":532,"type":40},"2025-05-08",{"date":534,"type":21},"2025-09-30",{"date":536,"type":21},"2027-06-30",{"name":538,"class":75},"Muğla Sıtkı Koçman University",{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":249,"sex":16,"minAge":546,"maxAge":547,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":101},"100575538","investigations-of-factors-associated-with-treatment-response-and-prognosis-in-anxiety-disorders-100575538","NCT06773585","Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders","IRPA","Inclusion Criteria\n\n1. Anxiety Behavior Group\n\n   * Adults aged 19-60 years.\n   * Diagnosed with an anxiety disorder based on DSM-5 diagnostic criteria, evaluated by a board-certified psychiatrist.\n   * Individuals who fully understand the study's purpose and process and provide informed consent.\n2. Healthy Control Group\n\n   * Adults aged 19-60 years.\n   * Individuals who report no psychiatric symptoms and are not taking any psychotropic medications.\n   * Individuals who fully understand the study's purpose and process and provide informed consent.\n\nExclusion Criteria:\n\n1. Anxiety Behavior Group\n\n   * Individuals unable to read the consent form.\n   * Individuals with difficulty using virtual reality devices.\n   * Individuals with a history of epileptic seizures, brain injuries, or neurological disorders.\n   * Individuals with severe physical illnesses (e.g., cancer, tuberculosis, severe cardiovascular diseases).\n   * Individuals with substance or alcohol use disorders.\n   * Individuals with pacemakers or implanted metallic devices.\n   * Pregnant individuals or those in vulnerable environments, such as institutional employees.\n2. Healthy Control Group\n\n   * Exclusion criteria for the Anxiety behavior group apply.\n   * Additionally, individuals with any current or past psychiatric disorders are excluded.","19 Years","60 Years",{"count":549,"type":21},185,"The purpose of this study is to build a comprehensive brain and behavioral dataset on anxiety disorders and identify clinical factors related to treatment response and prognosis in patients with anxiety disorders. By conducting an integrated analysis of clinical features (phenotypes), comorbid conditions, virtual reality (VR)-based behavioral data, electroencephalogram (EEG) data, and MRI-based data in patients undergoing treatment for anxiety disorders and healthy controls, this study aims to enhance the understanding of the pathophysiology of anxiety disorders and establish a foundation for precision medicine.\n\nAnxiety disorders significantly impair quality of life by inducing irrational fear and apprehension even in everyday situations. Over the past few years, the prevalence of anxiety disorders and associated medical expenses have surged, escalating the societal and economic burden. However, the current diagnostic system, DSM-5, relies on symptom-based approaches, which often lead to heterogeneity within the same diagnostic category. This limitation hinders the accurate prediction of treatment response and the design of optimal therapeutic strategies. To address these issues, the U.S. National Institute of Mental Health (NIMH) proposed the Research Domain Criteria (RDoC). RDoC is a multidimensional framework that integrates behavioral, psychological, and neurological data to facilitate the development of treatment strategies rooted in pathophysiology. Nonetheless, the acquisition of objective and reliable assessment data remains a challenge due to the inherent characteristics of mental disorders.\n\nVirtual reality (VR) technology has emerged as a promising solution to overcome these limitations. VR enables the creation of immersive 3D environments that can elicit anxiety-related behaviors and precisely evaluate them in controlled settings. It also allows data collection in scenarios that closely resemble real-life situations while offering advantages such as repeatability and ease of use. Combining behavioral data collected in VR environments with EEG data can provide a more detailed understanding of the neurophysiological representations underlying anxiety behaviors. EEG, as a biomarker reflecting neural activity in real time, facilitates intuitive and effective analyses. Moreover, MRI-based brain imaging plays a critical role in identifying structural and functional connectivity differences between anxiety disorder patients and healthy controls. It offers crucial insights into the biomarkers that predict treatment outcomes and prognosis.\n\nBy integrating these data, this study seeks to uncover the key factors influencing treatment response and prognosis in patients with anxiety disorders.",[28],[553,554,555],"panic disorder","anxiety disorder","panic attack","2025-04-27",{"date":511,"type":40},{"date":559,"type":21},"2025-05-15",{"date":561,"type":21},"2029-12-15",{"name":563,"class":75},"Kangbuk Samsung Hospital",{"id":565,"slug":566,"hasResults":11,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":58,"phases":574,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":489},"100431588","evaluation-of-primary-care-behavioral-health-pcbh-with-the-addition-of-self-help-cbt---a-randomized-multicenter-trial-100431588","NCT04900064","Evaluation of Primary Care Behavioral Health (PCBH) With the Addition of Self-help CBT - A Randomized Multicenter Trial","Evaluation of Primary Care Behavioral Health (PCBH) With the Addition of Self-help CBT - A Randomized Multicenter Trial for Superiority and Non-superiority Comparisons of Effects on Patients' Everyday Function, Symptoms, and Experiences","KAIROS","Inclusion Criteria:\n\n* All patients from age 18 who seek care at the PCC, who are deemed to be suitable for Behavioural Health interventions and booked to the mental health professionals at the PCC, according to screening methods and\u002For clinical assessments made by health care personnel at the PCC, will be included. This broad criteria reflects the naturalistic setting where decisions of clinicians, rather than highly standardized criteria, are the basis for inclusion.\n\nExclusion Criteria:\n\n* Does not speak Swedish well enough to fill out questionnaires or to receive self-help CBT in Swedish.\n* Is in need of emergency type care, like with suicidal ideation or behaviours, ongoing psychosis or mania.",{"count":573,"type":21},1242,[60],"In this multicenter study, the investigators want to find out if an addition of an diagnostic assessment and possibility of treatment with guided self-help CBT can increase the treatment effects of PCBH on patient functioning and symptoms, compared to standard PCBH which uses contextual assessment and brief interventions. In addition to this, the study will investigate the overall effect of PCBH on both patient and organisation level outcomes.",[28,66,376,577,578,65,579,580,581,63,582,583,584],"Hypochondriasis","Insomnia","Burnout","Adjustment Disorders","Stress, Psychological","Life Stress","Life Style Induced Illness","Psychological Distress","2025-04-08",{"date":587,"type":40},"2025-04-11",{"date":589,"type":40},"2021-06-14",{"date":591,"type":21},"2026-12-31",{"name":593,"class":75},"Linnaeus University",{"id":595,"slug":596,"hasResults":11,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":600,"targetDuration":4,"studyType":58,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":101},"100548571","the-effectiveness-of-transdiagnostic-cbt-protocol-on-anxiety-disorders-100548571","NCT06422728","The Effectiveness of Transdiagnostic CBT Protocol on Anxiety Disorders","Inclusion Criteria:\n\n* Being diagnosed with at least one of the following disorders in the pre-interview (SCID 5 interview for diagnosis): generalized anxiety disorder (GAD), panic disorder (PD), social anxiety disorder (SAD) or anxiety disorder not otherwise specified (NOS).\n\nExclusion Criteria:\n\n* Active substance use or having a psychiatric history related to substance use\n* Having a co-diagnosis of psychotic disorders or bipolar disorders\n* Receiving active psychotherapy support\n* Being not graduated from primary school",{"count":310,"type":21},[60],"The transdiagnostic approach argues that the common features are needed to be taken into account \\[e.g. distress intolerance (DI), intolerance of uncertainty (IU), worry)\\] underlying emotional disorders rather than evaluating them separately due to the fact that the dissection of anxiety disorders has increased with each emerging version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), in which the classification of anxiety disorders resulted in an increased number of intervention protocols for each disorder. This also caused an increase of comorbidity among anxiety disorders. Transdiagnostic approach offers a unified protocol (UP) for strengthening the common features, and thereby both preventing the emergence of emotional disorders or intervening the symptom severity of emotional disorders, which can be applied to different types of emotional disorders. The main aim of this study is to develop a UP which is planned to be applied as a group therapy. The UP will include interventions developing the levels of common transdiagnostic features (DI, IU and worry). The study's second aim is to investigate the effect of the developed UP on DI, IU and worry. The third one is to search the effect of the developed UP on symptom severity levels of anxiety disorders. Fourthly, this study will search if the levels of transdiagnostic common features (DI, IU and worry) will predict the levels of symptom severity of anxiety disorders'.",[156,66,65,28,604],"Anxiety Disorder NOS",[606,607,286,608,129],"transdiagnostic approach","unified protocol,","CBT","2024-09-03",{"date":611,"type":40},"2024-09-19",{"date":613,"type":40},"2024-06-20",{"date":615,"type":21},"2025-01",{"name":617,"class":75},"Ibn Haldun University",{"id":619,"slug":620,"hasResults":11,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":249,"sex":16,"minAge":546,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":58,"phases":627,"briefSummary":628,"conditions":629,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":101},"100479786","risk-and-resiliency-factors-in-the-rcmp-a-prospective-investigation-100479786","NCT05527509","Risk and Resiliency Factors in the RCMP: A Prospective Investigation","Inclusion Criteria:\n\n* Cadets starting the RCMP Cadet Training Program\n\nExclusion Criteria:\n\n* Anyone other than cadets starting the RCMP Cadet Training Program","57 Years",{"count":626,"type":21},960,[60],"The Royal Canadian Mounted Police (RCMP), like all public safety personnel (PSP), are frequently exposed to potentially psychologically traumatic events that contribute to posttraumatic stress injuries (PTSI). Addressing PTSI is impeded by the limited available research. The RCMP are working to build evidence-based solutions to PTSI and other mental health challenges facing their members, which by extension will help all PSP, as part of the Canadian Government Federal Framework on Posttraumatic Stress Disorder. A key element is the \"Longitudinal Study of Operational Stress Injuries \u002F Étude longitudinale sur les traumatismes liés au stress opérationnel\", a study which has been renamed \"Risk and Resiliency Factors in the RCMP: A Prospective Investigation\", and is referred to as the \"RCMP Study\" for short. The RCMP Study has been detailed online (www.rcmpstudy.ca) and in a recently published peer-reviewed protocol paper, \"The Royal Canadian Mounted Police (RCMP) Study: protocol for a prospective investigation of mental health risk and resilience factors\" (https:\u002F\u002Fdoi.org\u002F10.24095\u002Fhpcdp.42.8.02). The RCMP Study, part of the concerted efforts by the RCMP to reduce PTSI by improving access to evidence-based assessments, treatments, and training as well as participant recruitment and RCMP Study developments to date. The RCMP Study has been designed to (1) develop, deploy and assess the impact of a system for ongoing annual, monthly and daily evidence-based assessments; (2) evaluate associations between demographic variables and PTSI; (3) longitudinally assess individual differences associated with PTSI; (4) augment the RCMP Cadet Training Program with skills to proactively mitigate PTSI; and (5) assess the impact of the augmented training condition (ATC) versus the standard training condition (STC). Participants in the STC (n = 480) and ATC (n = 480) are assessed before and after training and annually for 5 years on their deployment date; they also complete brief monthly and daily surveys. The RCMP Study results are expected to benefit the mental health of all participants, RCMP and PSP by reducing PTSI among all who serve.",[399,157,28,65,397,630,631,632],"Traumatic Stress Disorder","Trauma and Stress Related Disorders","Vicarious Trauma","2023-11-27",{"date":635,"type":40},"2023-11-28",{"date":637,"type":40},"2019-04-22",{"date":639,"type":21},"2029-12",{"name":641,"class":75},"University of Regina",{"id":643,"slug":644,"hasResults":11,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":11,"sex":16,"minAge":546,"maxAge":547,"enrollmentInfo":649,"targetDuration":4,"studyType":58,"phases":650,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":4},"100495923","phase-4-efficacy-of-hydroxyzine-for-patients-with-panic-disorder-100495923","NCT05737511","Efficacy of Hydroxyzine for Patients With Panic Disorder","Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial.","Inclusion Criteria:\n\n* The study will recruit adult patients (18 years and older)\n* Confirmed diagnosis of the panic disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).\n* Participants will be included if they have had at least one panic attack per week for the last four weeks,\n* Have not received any pharmacological treatment for panic disorder in the past four weeks,\n* Willing to discontinue any current benzodiazepine or SSRI treatment for the duration of the study.\n\nExclusion criteria:\n\n* Current substance abuse or dependence,\n* Medical diseases\n* Psychiatric comorbidities,\n* Pregnancy or lactation.",{"count":152,"type":21},[651],"PHASE4","The aim of this study is to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. By conducting a pilot study, we hope to provide initial data on the feasibility and potential impact of hydroxyzine for this population. This will inform the design and power calculations of a larger, more comprehensive study in the future.\n\nObjectives:\n\nTo assess the feasibility of conducting a randomized controlled trial (RCT) of hydroxyzine for panic disorder.\n\nTo evaluate the effectiveness of hydroxyzine compared to TAU in reducing panic symptoms in patients with panic disorder.\n\nTo explore the potential side effects and tolerability of hydroxyzine in this population.\n\nMethods:\n\nThis will be a single-center, open-label, randomized pilot study. A total of 30 patients with a primary diagnosis of panic disorder will be recruited from a psychiatric outpatient clinic. Participants will be randomly assigned to receive either hydroxyzine or TAU for 8 weeks. The primary outcome measure will be the change in panic symptoms as assessed by the Panic Disorder Severity Scale (PDSS). Secondary outcome measures will include the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression-Severity (CGI-S) scale. Participants will be assessed at baseline, 4 weeks, and 8 weeks. Adverse events will be monitored throughout the study.\n\nExpected Results:\n\nThis pilot study is expected to provide preliminary data on the feasibility and potential efficacy of hydroxyzine for panic disorder. The results will inform the design of a larger RCT to further evaluate the efficacy of hydroxyzine for this population.\n\nSignificance:\n\nThere is a need for effective and well-tolerated treatments for panic disorder. If found to be effective, hydroxyzine could provide a new option for patients with this condition, potentially improving their quality of life and functioning. The results of this pilot study will inform the design of future studies and contribute to the development of evidence-based treatments for panic disorder.",[28],"2023-02-20",{"date":656,"type":40},"2023-02-21",{"date":658,"type":21},"2023-12-30",{"date":660,"type":21},"2026-12-30",{"name":662,"class":75},"Sultan Qaboos University",{"id":664,"slug":665,"hasResults":11,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":249,"sex":16,"minAge":669,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":672,"conditions":673,"keywords":674,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":101},"100490235","neurobiological-markers-of-treatment-response-for-anxiety-and-ocd-100490235","NCT05663489","Neurobiological Markers of Treatment Response for Anxiety and OCD","Inclusion Criteria:\n\n* Diagnosed with obsessive-compulsive disorder, panic disorder or social anxiety disorder using DSM-5 criteria\n* Referred to National Clinic for 4-Day Treatment, Haukeland University Hospital, Bergen, Norway\n* Consented to participate in the \"Kvalitetsregister for konsentrerte behandlingsformat\"\n\nExclusion Criteria:\n\n* Suicidal, ongoing mania, primary eating disorder, intellectual disability, ongoing psychosis, ongoing substance abuse\n\nFor MRI substudy:\n\nInclusion Criteria:\n\n\\- For the healthy controls, no previous or current psychiatric disorders as detected by the Mini International Neuropsychiatric Interview (MINI)\n\nExclusion Criteria:\n\n\\- MRI incompatibility (e.g. pregnancy, metal implants)","16 Years",{"count":671,"type":21},500,"Obsessive-compulsive disorder (OCD) and anxiety disorders are common and debilitating conditions which are often chronic when treatment is not provided. International guidelines recommend cognitive behavioral therapy (CBT) as the first-line treatment, and research has shown that CBT can be delivered over a concentrated period of time. The Bergen 4-Day Treatment (B4DT) is an exposure-based treatment which is delivered over four consecutive days. B4DT has been shown to induce rapid and long-lasting remission in around 70% of patients. This provides a platform for studying psychological and neurobiological changes associated with treatment response and non-response. The present study will investigate longitudinal changes in psychological measures and DNA methylation in patients who receive the B4DT, as well as a subset will also undergo multimodal brain imaging.",[63,66,28],[675,676,677],"MRI","epigenetics","genetics","2022-12-15",{"date":680,"type":40},"2022-12-23",{"date":682,"type":40},"2018-03-23",{"date":684,"type":21},"2027-12-11",{"name":686,"class":75},"Haukeland University Hospital",{"id":688,"slug":689,"hasResults":11,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":693,"eligibilityCriteria":694,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":695,"targetDuration":4,"studyType":58,"phases":697,"briefSummary":698,"conditions":699,"keywords":701,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":703,"lastUpdatePostDateStruct":704,"startDateStruct":706,"completionDateStruct":708,"leadSponsor":710,"locationsCount":4},"100448372","testing-a-precision-psychotherapy-system-for-low-income-patients-100448372","NCT05118594","Testing a Precision Psychotherapy System for Low-income Patients","Open-trial to Prospectively Test the Feasibility of a Precision Psychotherapy System for Low-income Patients","ML_LMIC","Inclusion Criteria:\n\n* Diagnoses of a depressive disorder (i.e., major depressive disorder or dysthymic disorder) or an anxiety disorder (i.e., specific phobia, social anxiety disorder, panic disorder, agoraphobia or generalized anxiety disorder) determined with the Mini-International Neuropsychiatric Interview (MINI)\n* A score of at least two (mild) in any the five items from the depression and anxiety domains of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult\n* A total family income below the poverty index threshold, determined by a Licensed Social Worker\n* Aged 18 to 65\n* Fluency in Spanish language\n* Capacity to consent\n\nExclusion Criteria:\n\n* Psychosis\n* Mania\n* Suicidal ideation with intent and\u002For plan\n* Substance abuse disorders\n* History of organic mental disease.",{"count":696,"type":21},111,[60],"The purpose of this study is to evaluate the feasibility of an evidence-based system to recommend core interventions, before the beginning of treatment, to psychotherapists treating low-income patients with depressive or anxiety disorders.",[157,700,284,66,28,121,65],"Dysthymic Disorder",[702,319],"Depressive disorders","2021-11-11",{"date":705,"type":40},"2021-11-18",{"date":707,"type":21},"2026-02",{"date":709,"type":21},"2026-11",{"name":711,"class":269},"National Council of Scientific and Technical Research, Argentina"]